Chris Garabe­di­an's first Xon­toge­ny com­pa­ny, Lan­dos Bio­phar­ma, preps a nine-fig­ure IPO as lead pro­gram heads to PhI­II

Lan­dos Bio­phar­ma, the lead com­pa­ny in the port­fo­lio of Chris Garabe­di­an’s fund with Per­cep­tive, is prepar­ing to go pub­lic about a year and a half since its last raise. But the com­pa­ny’s last da­ta dump missed on all its pri­ma­ry end­points in IBD de­spite “pos­i­tive” signs it mea­sured up with stan­dard of care — will in­vestors be im­pressed?

The for­mer Vir­ginia Tech spin­out filed for a $100 mil­lion IPO late Wednes­day, aim­ing to take its AI-based pre­ci­sion med­i­cine plat­form and lead pro­gram to Nas­daq. Once the biotech prices, it will trade on the tick­er $LABP.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER